Phase Ib Safety, Two-Dose Study of MultiGeneAngio in Patients with Chronic Critical Limb Ischemia

Molecular Therapy

Volumn 25, Issue 3, 2017, Pages 816-825

  Flugelman, Moshe Y ^a,b,c   Halak, Moshe ^d,e   Yoffe, Boris ^f,g   Schneiderman, Jacob ^e   Rubinstein, Chen ^h   Bloom, Allan Isaac ^h   Weinmann, Eran ⁱ   Goldin, Ilya ^j   Ginzburg, Victor ^g,k   Mayzler, Olga ^g,k   Hoffman, Aaron ^b,l   Koren, Belly ^c   Gershtein, Diana ^c   Inbar, Michal ^c   Hutoran, Marina ^c   Tsaba, Adili ^b,c  

^a CARMEL MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c VESSL Therapeutics Ltd   (Israel)

^d SHEBA MEDICAL CENTER   (Israel)

^e TEL AVIV UNIVERSITY   (Israel)

^f BARZILAI MEDICAL CENTER   (Israel)

^g BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^h HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

ⁱ KAPLAN MEDICAL CENTER   (Israel)

^j SHAARE ZEDEK MEDICAL CENTER   (Israel)

^k BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^l Rambam Health Care Campus ^*  (Israel)

more..

Author keywords

Ang 1; cell therapy; critical limb ischemia; gene therapy; VEGF

Indexed keywords

ANGIOPOIETIN 1; VASCULOTROPIN; ANGIOGENIC PROTEIN;

AGED; ANGIOGENESIS; ARTICLE; AUTOLOGOUS VENOUS ENDOTHELIAL CELL TRANSPLANTATION; AUTOLOGOUS VENOUS SMOOTH MUSCLE CELL TRANSPLANTATION; CELL TRANSPLANTATION; CLAUDICATION; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CRITICAL LIMB ISCHEMIA; DISEASE CLASSIFICATION; ENDOTHELIUM CELL; EVENT FREE SURVIVAL; FEMALE; HUMAN; LIMB AMPUTATION; LIMB PAIN; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SKIN ULCER; TREATMENT INDICATION; TREATMENT RESPONSE; VASCULAR SMOOTH MUSCLE CELL; ADMINISTRATION AND DOSAGE; CLINICAL TRIAL; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; ISCHEMIA; LOWER LIMB; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PROCEDURES; QUALITY OF LIFE; RETROVIRIDAE; SMOOTH MUSCLE CELL; TRANSGENE; TREATMENT OUTCOME; VASCULARIZATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOGENIC PROTEINS; COMBINED MODALITY THERAPY; ENDOTHELIAL CELLS; FEMALE; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HUMANS; ISCHEMIA; LOWER EXTREMITY; MALE; MIDDLE AGED; MYOCYTES, SMOOTH MUSCLE; QUALITY OF LIFE; RETROVIRIDAE; TRANSDUCTION, GENETIC; TRANSGENES; TREATMENT OUTCOME;

EID: 85016258629     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1016/j.ymthe.2016.12.019     Document Type: Article

References (38)

1. 1 Varu, V.N., Hogg, M.E., Kibbe, M.R., Critical limb ischemia. J. Vasc. Surg. 51 (2010), 230–241.
2. 2 Rutherford, R.B., Baker, J.D., Ernst, C., Johnston, K.W., Porter, J.M., Ahn, S., Jones, D.N., Recommended standards for reports dealing with lower extremity ischemia: revised version. J. Vasc. Surg. 26 (1997), 517–538.
3. 3 Abu Dabrh, A.M., Steffen, M.W., Undavalli, C., Asi, N., Wang, Z., Elamin, M.B., Conte, M.S., Murad, M.H., The natural history of untreated severe or critical limb ischemia. J. Vasc. Surg. 62 (2015), 1642–1651.e3.
4. 4 Benoit, E., O'Donnell, T.F. Jr., Kitsios, G.D., Iafrati, M.D., Improved amputation-free survival in unreconstructable critical limb ischemia and its implications for clinical trial design and quality measurement. J. Vasc. Surg. 55 (2012), 781–789.
5. 5 Marston, W.A., Davies, S.W., Armstrong, B., Farber, M.A., Mendes, R.C., Fulton, J.J., Keagy, B.A., Natural history of limbs with arterial insufficiency and chronic ulceration treated without revascularization. J. Vasc. Surg. 44 (2006), 108–114.
6. 6 Melillo, E., Micheletti, L., Nuti, M., Dell'Omo, G., Berchiolli, R., Adami, D., Farina, A., Panigada, G., Meini, S., Long-term clinical outcomes in critical limb ischemia—A retrospective study of 181 patients. Eur. Rev. Med. Pharmacol. Sci. 20 (2016), 502–508.
7. 7 Biancari, F., Meta-analysis of the prevalence, incidence and natural history of critical limb ischemia. J. Cardiovasc. Surg. (Torino) 54 (2013), 663–669.
8. 8 Dohmen, A., Eder, S., Euringer, W., Zeller, T., Beyersdorf, F., Chronic critical limb ischemia. Dtsch. Arztebl. Int. 109 (2012), 95–101.
9. 9 Becker, F., Robert-Ebadi, H., Ricco, J.-B., Setacci, C., Cao, P., de Donato, G., Eckstein, H.H., De Rango, P., Diehm, N., Schmidli, J., et al. Chapter I: Definitions, epidemiology, clinical presentation and prognosis. Eur. J. Vasc. Endovasc. Surg. 42:Suppl 2 (2011), S4–S12.
10. 10 Fowkes, F.G., Rudan, D., Rudan, I., Aboyans, V., Denenberg, J.O., McDermott, M.M., Norman, P.E., Sampson, U.K., Williams, L.J., Mensah, G.A., Criqui, M.H., Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet 382 (2013), 1329–1340.
11. 11 Staudacher, D.L., Preis, M., Lewis, B.S., Grossman, P.M., Flugelman, M.Y., Cellular and molecular therapeutic modalities for arterial obstructive syndromes. Pharmacol. Ther. 109 (2006), 263–273.
12. 12 Grochot-Przeczek, A., Dulak, J., Jozkowicz, A., Therapeutic angiogenesis for revascularization in peripheral artery disease. Gene 525 (2013), 220–228.
13. 13 Semenza, G.L., Vasculogenesis, angiogenesis, and arteriogenesis: Mechanisms of blood vessel formation and remodeling. J. Cell. Biochem. 102 (2007), 840–847.
14. 14 Carmeliet, P., Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 6 (2000), 389–395.
15. 15 Cai, W., Schaper, W., Mechanisms of arteriogenesis. Acta Biochim. Biophys. Sin. (Shanghai) 40 (2008), 681–692.
16. 16 Staudacher, D.L., Flugelman, M.Y., Cell and gene therapies in cardiovascular disease with special focus on the no option patient. Curr. Gene Ther. 6 (2006), 609–623.
17. 17 Ouma, G.O., Zafrir, B., Mohler, E.R. 3rd, Flugelman, M.Y., Therapeutic angiogenesis in critical limb ischemia. Angiology 64 (2013), 466–480.
18. 18 Teraa, M., Sprengers, R.W., Schutgens, R.E., Slaper-Cortenbach, I.C., van der Graaf, Y., Algra, A., van der Tweel, I., Doevendans, P.A., Mali, W.P., Moll, F.L., Verhaar, M.C., Effect of repetitive intra-arterial infusion of bone marrow mononuclear cells in patients with no-option limb ischemia: the randomized, double-blind, placebo-controlled Rejuvenating Endothelial Progenitor Cells via Transcutaneous Intra-arterial Supplementation (JUVENTAS) trial. Circulation 131 (2015), 851–860.
19. 19 Gluzman, Z., Koren, B., Preis, M., Cohen, T., Tsaba, A., Cosset, F.L., Shofti, R., Lewis, B.S., Virmani, R., Flugelman, M.Y., Endothelial cells are activated by angiopoeitin-1 gene transfer and produce coordinated sprouting in vitro and arteriogenesis in vivo. Biochem. Biophys. Res. Commun. 359 (2007), 263–268.
20. 20 Grossman, P.M., Mohler, E.R. 3rd, Roessler, B.J., Wilensky, R.L., Levine, B.L., Woo, E.Y., Upchurch, G.R. Jr., Schneiderman, J., Koren, B., Hutoran, M., et al. Phase I study of multi-gene cell therapy in patients with peripheral artery disease. Vasc. Med. 21 (2016), 21–32.
21. 21 Ylä-Herttuala, S., Rissanen, T.T., Vajanto, I., Hartikainen, J., Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. J. Am. Coll. Cardiol. 49 (2007), 1015–1026.
22. 22 Ferrara, N., Vascular endothelial growth factor. Arterioscler. Thromb. Vasc. Biol. 29 (2009), 789–791.
23. 23 Thurston, G., Suri, C., Smith, K., McClain, J., Sato, T.N., Yancopoulos, G.D., McDonald, D.M., Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 286 (1999), 2511–2514.
24. 24 Thurston, G., Wang, Q., Baffert, F., Rudge, J., Papadopoulos, N., Jean-Guillaume, D., Wiegand, S., Yancopoulos, G.D., McDonald, D.M., Angiopoietin 1 causes vessel enlargement, without angiogenic sprouting, during a critical developmental period. Development 132 (2005), 3317–3326.
25. 25 Shiraki, T., Iida, O., Takahara, M., Okamoto, S., Kitano, I., Tsuji, Y., Terashi, H., Uematsu, M., Predictive scoring model of mortality after surgical or endovascular revascularization in patients with critical limb ischemia. J. Vasc. Surg. 60 (2014), 383–389.
26. 26 Hawkins, A.T., Schaumeier, M.J., Smith, A.D., Hevelone, N.D., Nguyen, L.L., When to call it a day: Incremental risk of amputation and death after multiple revascularization. Ann. Vasc. Surg. 28 (2014), 35–47.
27. 27 Henry, A.J., Hevelone, N.D., Belkin, M., Nguyen, L.L., Socioeconomic and hospital-related predictors of amputation for critical limb ischemia. J. Vasc. Surg. 53 (2011), 330–339.e1.
28. 28 Eslami, M.H., Zayaruzny, M., Fitzgerald, G.A., The adverse effects of race, insurance status, and low income on the rate of amputation in patients presenting with lower extremity ischemia. J. Vasc. Surg. 45 (2007), 55–59.
29. 29 Goodney, P.P., Travis, L.L., Nallamothu, B.K., Holman, K., Suckow, B., Henke, P.K., Lucas, F.L., Goodman, D.C., Birkmeyer, J.D., Fisher, E.S., Variation in the use of lower extremity vascular procedures for critical limb ischemia. Circ. Cardiovasc. Qual. Outcomes 5 (2012), 94–102.
30. 30 Kinlay, S., Outcomes for clinical studies assessing drug and revascularization therapies for claudication and critical limb ischemia in peripheral artery disease. Circulation 127 (2013), 1241–1250.
31. 31 Conte, M.S., Understanding objective performance goals for critical limb ischemia trials. Semin. Vasc. Surg. 23 (2010), 129–137.
32. 32 Pan, Z., Fukuoka, S., Karagianni, N., Guaiquil, V.H., Rosenblatt, M.I., Vascular endothelial growth factor promotes anatomical and functional recovery of injured peripheral nerves in the avascular cornea. FASEB J. 27 (2013), 2756–2767.
33. 33 Koren, B., Weisz, A., Fischer, L., Gluzman, Z., Preis, M., Avramovitz, N., Cohen, T., Cosset, F.L., Lewis, B.S., Flugelman, M.Y., Efficient transduction and seeding of human endothelial cells onto metallic stents using bicistronic pseudo-typed retroviral vectors encoding vascular endothelial growth factor. Cardiovasc. Revasc. Med. 7 (2006), 173–178.
34. 34 Landry, G.J., Functional outcome of critical limb ischemia. J. Vasc. Surg. 45:Suppl A (2007), A141–A148.
35. 35 Ware, J.E. Jr., SF-36 health survey update. Spine 25 (2000), 3130–3139.
36. 36 Simonsick, E.M., Gardner, A.W., Poehlman, E.T., Assessment of physical function and exercise tolerance in older adults: reproducibility and comparability of five measures. Aging (Milano) 12 (2000), 274–280.
37. 37 Peeters, P., Mets, T., The 6-minute walk as an appropriate exercise test in elderly patients with chronic heart failure. J. Gerontol. A Biol. Sci. Med. Sci. 51 (1996), M147–M151.
38. 38 Montgomery, P.S., Gardner, A.W., The clinical utility of a six-minute walk test in peripheral arterial occlusive disease patients. J. Am. Geriatr. Soc. 46 (1998), 706–711.